Finding your next opportunity shouldn’t require piecing together multiple databases, alerts and research tools.
Fundz combines its own funding and M&A intelligence with hiring, leadership and other business signals into one connected view of each company, ranks opportunities against your ideal customer profile, and delivers the evidence and verified contacts to act on. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
OracleSnowflakeCloudflareLinkedInGoogleSalesforce
★★★★★4.8/5 on G2· Since 2015
Matchpoint Therapeutics secures $150 million in Series B financing led by Nextech Invest and Norwest. The funding will advance clinical development of MPT-062 for autoimmune and inflammatory diseases.
Matchpoint Therapeutics successfully closed a $150 million Series B financing to support the clinical development of its lead asset, MPT-062. The financing was co-led by Nextech Invest and Norwest, with participation from both new and existing investors. This funding will further progress Matchpoint's product pipeline, which includes innovative therapies for autoimmune and inflammatory diseases. The company looks forward to advancing its programs with the support of its investors.
Company Information
Company
Matchpoint Therapeutics
Location
ONE KENDALL SQUARE
Cambridge, Maryland, United States
About
Matchpoint is a biotechnology company harnessing the power of covalency to discover precision covalent medicines to transform the treatment of immune diseases and other serious illnesses. The company's proprietary Advanced Covalent Exploration (ACE) platform integrates advanced chemoproteomics, machine learning and covalent chemistry library evolution. Matchpoint has an emerging pipeline of novel covalent medicines initially focused on immunology. For more information, please visit www.matchpointtx.com.
Fundz sees it the moment Matchpoint Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
CambridgeHealthcare